Microbial activities of gut commensals have been linked to several host diseases. In recent work, Roberts et al. (2018) develop therapeutics targeting microbial production of the metabolite trimethylamine (TMA), which has been linked to cardiovascular disease. This microbiota-based approach holds promise for efficacious therapies that may also reduce host side effects.
Copyright © 2018 Elsevier Inc. All rights reserved.